Oncostatin-M-Reactive Pericytes Aggravate Blood-Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro

被引:18
|
作者
Takata, Fuyuko [1 ]
Dohgu, Shinya [1 ]
Sakaguchi, Shinya [1 ]
Sakai, Kenta [1 ]
Yamanaka, Gaku [2 ]
Iwao, Takuro [1 ]
Matsumoto, Junichi [1 ]
Kimura, Ikuya [1 ]
Sezaki, Yume [1 ]
Tanaka, Yoshie [1 ]
Yamauchi, Atsushi [1 ]
Kataoka, Yasufumi [1 ]
机构
[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka, Fukuoka 8140180, Japan
[2] Tokyo Med Univ, Dept Pediat, Shinjuku Ku, Tokyo 1600023, Japan
基金
日本学术振兴会;
关键词
oncostatin M; pericytes; brain endothelial cells; STAT3; ruxolitinib; blood-brain barrier; LYMPHOMONONUCLEAR CELLS; ALPHA; EXPRESSION; CYTOKINE; BETA;
D O I
10.1016/j.neuroscience.2019.10.014
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oncostatin M (OSM) is a cytokine of the interleukin (IL)-6 family members. It induces blood-brain barrier (BBB) dysfunction by activating Janus-activated kinase (JAK) and signal transducer and activator of transcription (STAT) 3 pathways in brain endothelial cells. Brain pericytes located around microvessels are one of the BBB constituents. Pericytes work as a boundary surface between the blood circulation and brain parenchyma, and their functions are altered under pathophysiological conditions, leading to BBB dysregulation. However, it remains unknown whether pericytes are associated with OSM-induced BBB dysfunction. We demonstrated that pericyte exposure to OSM (100 ng/mL) elevated phosphorylation of STAT3, a main OSM signaling pathway, and that pericytes expressed OSM receptors (OSMRs) including OSMR beta and glycoprotein 130. These results suggest that pericytes are able to respond to OSM. To determine the effects of OSM-reactive pericytes on BBB functions, rat brain endothelial cell (RBEC) monolayers were cultured with OSM-treated pericytes. The presence of pericytes exposed to 100 ng/mL of OSM for 48 h aggravated both the elevated permeability to sodium fluorescein and the lowered transendothelial electrical resistance which were induced by OSM in RBECs. This OSM-reactive pericyte-induced aggravation of lowered RBEC barrier function was reversed by ruxolitinib, a JAK inhibitor. These findings suggest that activated JAK/STAT3 signaling in pericytes contributes to OSM-produced BBB breakdown. Thus, OSM-reactive pericytes may have to be considered a characteristic machinery in the formation and progression of BBB breakdown under pathological conditions associated with increased OSM levels. (C) 2019 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 40 条
  • [1] Oncostatin M-induced blood-brain barrier impairment is due to prolonged activation of STAT3 signaling in vitro
    Takata, Fuyuko
    Dohgu, Shinya
    Matsumoto, Junichi
    Machida, Takashi
    Sakaguchi, Shinya
    Kimura, Ikuya
    Yamauchi, Atsushi
    Kataoka, Yasufumi
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (11) : 9055 - 9063
  • [2] Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages
    Zhang, Xin
    Li, Jing
    Qin, Juan-Juan
    Cheng, Wen-Lin
    Zhu, Xueyong
    Gong, Fu-Han
    She, Zhigang
    Huang, Zan
    Xia, Hao
    Li, Hongliang
    JOURNAL OF LIPID RESEARCH, 2017, 58 (05) : 895 - 906
  • [3] A2 Astrocytes Counteract the Blood-Brain Barrier Dysfunction Via α7nAChR/JAK2/STAT3 Signaling in HIV-Associated Neurocognitive Disorders
    Lun, Jingxian
    Li, Yubin
    Gao, Xuefeng
    Gong, Zelong
    Zou, Jinhu
    Lin, Qiongxi
    Huang, Pengwei
    Long, Min
    Cao, Hong
    BLOOD, 2022, 140 : 2618 - 2619
  • [4] Tetramethylpyrazine attenuates blood-brain barrier disruption in ischemia/ reperfusion injury through the JAK/STAT signaling pathway
    Gong, Pian
    Zhang, Zhan
    Zou, Yichun
    Tian, Qi
    Han, Shoumeng
    Xu, Zhou
    Liao, Jianming
    Gao, Ling
    Chen, Qianxue
    Li, Mingchang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 854 : 289 - 297
  • [5] Contribution of thrombin-reactive brain pericytes to blood-brain barrier dysfunction in an in vivo mouse model of obesity-associated diabetes and an in vitro rat model
    Machida, Takashi
    Takata, Fuyuko
    Matsumoto, Junichi
    Miyamura, Tomoyuki
    Hirata, Ryosuke
    Kimura, Ikuya
    Kataoka, Yasufumi
    Dohgu, Shinya
    Yamauchi, Atsushi
    PLOS ONE, 2017, 12 (05):
  • [6] Cancer-Associated Adipose Tissue Promotes Breast Cancer Progression by Paracrine Oncostatin M and Jak/STAT3 Signaling
    Lapeire, Lore
    Hendrix, An
    Lambein, Kathleen
    Van Bockstal, Mieke
    Braems, Geert
    Van Den Broecke, Rudy
    Limame, Ridha
    Mestdagh, Pieter
    Vandesompele, Jo
    Vanhove, Christian
    Maynard, Dawn
    Lehuede, Camille
    Muller, Catherine
    Valet, Philippe
    Gespach, Christian P.
    Bracke, Marc
    Cocquyt, Veronique
    Denys, Hannelore
    De Wever, Olivier
    CANCER RESEARCH, 2014, 74 (23) : 6806 - 6819
  • [7] Organization of Endothelial Cells, Pericytes, and Astrocytes into a 3D Microfluidic in Vitro Model of the Blood-Brain Barrier
    Wang, Jack D.
    Khafagy, El-Sayed
    Khanafer, Khalil
    Takayama, Shuichi
    Elsayed, Mohamed E. H.
    MOLECULAR PHARMACEUTICS, 2016, 13 (03) : 895 - 906
  • [8] Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease
    Shin, Yoojin
    Choi, Se Hoon
    Kim, Eunhee
    Bylykbash, Enjana
    Kim, Jeong Ah
    Chung, Seok
    Kim, Doo Yeon
    Kamm, Roger D.
    Tanzi, Rudolph E.
    ADVANCED SCIENCE, 2019, 6 (20)
  • [9] Oncostatin M stimulates immature Leydig cell proliferation but inhibits its maturation and function in rats through JAK1/STAT3 signaling and induction of oxidative stress in vitro
    Tian, Lili
    Li, Xueyun
    Wang, Yiyan
    Chen, Quanxu
    Li, Xiaoheng
    Ge, Ren-Shan
    Li, Xingwang
    ANDROLOGY, 2022, 10 (02) : 354 - 366
  • [10] Inhibitory effect of baricitinib on microglia and STAT3 in a region with a weak blood-brain barrier in a mouse model of rheumatoid arthritis
    Matsushita, Takayuki
    Otani, Kazuhiro
    Yoshiga, Masayuki
    Hirano, Masashi
    Noda, Kentaro
    Kurosaka, Daitaro
    RHEUMATOLOGY, 2023, 62 (08) : 2908 - 2917